English

Klaria Interim Report Q1 2021

Report this content

Klaria Interim Report Q1 2021

Summary of the Interim Report

Option agreement for the US rights to Epinephrine Alginate Film signed with Imbrium Therapeutics

FIRST QUARTER 2021

  • Net sales amounted to 0.0 MSEK (0.0 MSEK)
  • Other income amounted to 31.3 MSEK (1.5 MSEK)
  • R&D costs for the period amounted to 11.4 MSEK (8.0 MSEK)
  • Profit after tax amounted to 16.7 MSEK (-11.0 MSEK)
  • Earnings per share for the quarter amounted to 0.32 SEK (-0.32 SEK)
  • Cash flow from operating activities amounted to 17.1 MSEK (0.4 MSEK)
  • Cash and cash equivalents on the balance day amounted to 48.2 MSEK (16.4 MSEK)
  • Shareholder’s equity per March 31, amounted to 126.3 MSEK (99.5 MSEK)
  • Klaria has received an upfront payment of 30.5 MSEK from Imbrium Therapuetics in connection with the signing of an option agreeement for the marketing rights to the drug candidate Epinephrine Alginate Film for treatment of serious allergic reactions.

EVENTS AFTER THE END OF THE PERIOD

  • Klaria receives third payment of approx. 2.2 MSEK from the EU Horizon 2020 program supporting the development of Sumatriptan Alginate Film.
  • Klaria announces successful outcome of pivotal bioequivalence study with Sumatriptan Alginate Film.
  • Klaria’s subsidiary Cannabis Delivery Sciences (CDS) signs strategic collaboration agreement with Pure Jamaican Limited.

For more information, visit the  Klaria Pharma Holding website klaria.com or contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99

 

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.

Subscribe

Documents & Links